Immunogenicity, Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Hib-MenCY-TT (MenHibrix®) Vaccine Compared to Merck & Co, Inc. PedvaxHIB Vaccine in Healthy Infants and Toddlers 12 to 15 Months of Age

NCT01978093 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

600

Enrollment

INDUSTRY

Sponsor class

Conditions

Neisseria Meningitidis
Haemophilus Influenzae Type b

Interventions

BIOLOGICAL: Hib-MenCY-TT (MenHibrix®)
BIOLOGICAL: Pediarix®
BIOLOGICAL: Rotarix®
BIOLOGICAL: Prevnar 13®
BIOLOGICAL: PedvaxHIB®
BIOLOGICAL: Havrix®

Sponsor

GlaxoSmithKline